Table 1 Description of the datasets used in this study
# | Cancer | No. of tumour samples | No. of normal samples |
|---|---|---|---|
1 | Bladder urothelial carcinoma (BLCA) | 408 | 19 |
2 | Thyroid carcinoma (THCA) | 501 | 59 |
3 | Cervical and endocervical cancers (CESC) | 304 | 3 |
4 | Cholangiocarcinoma (CHOL) | 36 | 9 |
5 | Colon adenocarcinoma (COAD) | 458 | 41 |
6 | Esophageal carcinoma (ESCA) | 184 | 13 |
7 | Glioblastoma multiforme (GBM) | 153 | 5 |
8 | Thymoma (THYM) | 120 | 2 |
9 | Head and neck squamous cell carcinoma (HNSC) | 520 | 44 |
10 | Kidney chromophobe (KICH) | 66 | 25 |
11 | Kidney renal clear cell carcinoma (KIRC) | 533 | 72 |
12 | Kidney renal papillary cell carcinoma (KIRP) | 290 | 32 |
13 | Liver hepatocellular carcinoma (LIHC) | 371 | 50 |
14 | Lung adenocarcinoma (LUAD) | 515 | 59 |
15 | Lung squamous cell carcinoma (LUSC) | 501 | 51 |
16 | Pancreatic adenocarcinoma (PAAD) | 178 | 4 |
17 | Uterine corpus endometrial carcinoma (UCEC) | 176 | 35 |
18 | Pheochromocytoma and paraganglioma (PCPG) | 179 | 3 |
19 | Rectum adenocarcinoma (READ) | 94 | 10 |
20 | Sarcoma (SARC) | 259 | 2 |
21 | Skin cutaneous melanoma (SKCM) | 103 | 1 |
22 | Stomach adenocarcinoma (STAD) | 415 | 37 |